Since single cases have shown a synergistic effect of PD-1 blockade and CAR T cells in PD-L+ lymphoma patients, the combination of CD30-specific CAR T cells and PD-1 blocking antibodies in cHL patients is intriguing and might reveal synergistic activity. Here, TNFRSF8 is linked to classic Hodgkin lymphoma.